Baird lowered the firm’s price target on Iqvia to $235 from $241 and keeps a Neutral rating on the shares. The firm sees a moderate recovery in TAS and RDS CDO growth but more importantly TAS has to pick up steam soon, as big Q4 ramp required remains a difficult to insurmountable sentiment hurdle for most investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $255 from $275 at Barclays
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Dollar Tree downgraded, Lululemon upgraded: Wall Street’s top analyst calls
- Iqvia initiated with a Buy at Goldman Sachs
- Here’s what Wall Street experts are saying about Salesforce ahead of earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue